Aptose Biosciences Inc (APTO)

[Tartiaboy]

Not very impressive. I suggest you look at ONCT presentation slides. They have an r/rMCL trial underway with zilovertamab + Ibrutinib. In r/r MCL they have ORR of 89% and CR of 43%. Median PFS not reached yet at 19.5 months follow-up.

Pirtobrutinib may be better than Ibrutinib monotherapy, but I don't think it will out perform Zilo + Ibrutinib combination.

I hold as much ONCT as I do APTO because of the potential of Zilovertamab in these B-cell malignancies. Also look at the combination efficacy for CLL. It's knock-out data. Happy to discuss this on the ONCT board if you are interested.